Trials / Completed
CompletedNCT01703572
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- OncoMed Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory lymphoid malignancies. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OMP-52M51 |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2012-10-10
- Last updated
- 2020-09-09
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01703572. Inclusion in this directory is not an endorsement.